<abstract xmlns="http://www.w3.org/1999/xhtml"><p>Benign prostatic hypertrophy (BPH) has become a major global health problem both in its frequency by which it determines the complications and the problems of diagnosis and treatment it requires. BPH is a heterogeneous disease. The symptoms attributed to BPH may have other coexisting causes and growth factors both androgen-dependent and independent, which promotes prostate enlargement. It is well known that prostate size correlates poorly with the symptoms so that reducing prostate using 5-alphareductase or alphablocants inhibitors may not always be sufficient. A better understanding of the pathophysiology of BPH and its interactions with other drugs will help the development of new substances with a better efficiency. This present work aims to be a modest contribution related to medical treatment in benign prostatic hyperplasia and the role that the generalist practitioner should play in managing of this urinary disease quite common in elderly men.</p></abstract>

Benign prostatic hypertrophy (BPH) has become a major global health problem both in its frequency by which it determines the complications and the problems of diagnosis and treatment it requires. BPH is a heterogeneous disease. The symptoms attributed to BPH may have other coexisting causes and growth factors both androgen-dependent and independent, which promotes prostate enlargement. It is well known that prostate size correlates poorly with the symptoms so that reducing prostate using 5-alphareductase or alphablocants inhibitors may not always be sufficient. A better understanding of the pathophysiology of BPH and its interactions with other drugs will help the development of new substances with a better efficiency. This present work aims to be a modest contribution related to medical treatment in benign prostatic hyperplasia and the role that the generalist practitioner should play in managing of this urinary disease quite common in elderly men.

Consideration of Drug Therapy in Benign Prostatic Hypertrophy

Doctoral School of Medicine, University “Ovidius” Constanta, Romania

ARS Medica Tomitana

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"Consideration of Drug Therapy in Benign Prostatic Hypertrophy"}

Benign prostatic hypertrophy (BPH) has become a major global health problem both in its frequency by which it determines the complications and the problems of...

Consideration of Drug Therapy in Benign Prostatic Hypertrophy

Data publikacji: 31 sty 2015

Zakres stron: 129 - 134

DOI: https://doi.org/10.2478/arsm-2014-0023

© 2015 Diamantis G. and Tode V.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.